CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+51.74%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$645M
AUM Growth
+$645M
(+33%)
Cap. Flow
+$46.7M
Cap. Flow
% of AUM
7.24%
Top 10 Holdings %
Top 10 Hldgs %
48.69%
Holding
75
New
11
Increased
16
Reduced
10
Closed
6
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
$33.6M |
| 2 |
Alkermes
ALKS
|
$20.5M |
| 3 |
RGLS
Regulus Therapeutics
RGLS
|
$14.4M |
| 4 |
Ardelyx
ARDX
|
$12.6M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$11.3M |
Top Sells
| 1 |
Puma Biotechnology
PBYI
|
$54.4M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$16.1M |
| 3 |
Arrowhead Research
ARWR
|
$13.3M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$13.1M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$6.14M |
Sector Composition
| 1 | Healthcare | 69.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $78.6M | 12.12% | 641,800 -106,900 | -14% | -$13.1M |
|
|
2
Puma Biotechnology
PBYI
$254M
| $41.6M | 6.42% | 220,000 -287,500 | -57% | -$54.4M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $33.6M | 5.17% | +300,000 | New | +$33.6M |
|
4
Tempest Therapeutics
TPST
$44M
| $33M | 5.09% | 747,000 +230,800 | +45% | +$10.2M |
|
|
5
Alkermes
ALKS
$4.78B
| $26.4M | 4.06% | 450,000 +350,000 | +350% | +$20.5M |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $22.3M | 3.44% | 1,000,000 +150,000 | +18% | +$3.35M |
|
|
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
| $21.1M | 3.25% | 1,500,000 | – | – |
|
|
8
Ardelyx
ARDX
$1.53B
| $19.9M | 3.07% | 1,053,500 +664,800 | +171% | +$12.6M |
|
|
QTNT
9
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $19.8M | 3.05% | 1,100,000 +600,000 | +120% | +$10.8M |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $17.6M | 2.72% | 1,100,000 +900,000 | +450% | +$14.4M |
|
|
SRNE
11
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $17.6M | 2.72% | 1,750,000 +750,000 | +75% | +$7.55M |
|
|
PTLA
12
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $17M | 2.62% | 600,000 +400,000 | +200% | +$11.3M |
|
|
CMRX
13
DELISTED
Chimerix, Inc.
CMRX
| $16.1M | 2.48% | 400,000 +150,000 | +60% | +$6.04M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $14.8M | 2.28% | 250,000 +100,000 | +67% | +$5.9M |
|
|
KITE
15
DELISTED
Kite Pharma, Inc.
KITE
| $14.7M | 2.27% | 255,000 +155,000 | +155% | +$8.94M |
|
16
Omeros
OMER
$283M
| $14.4M | 2.22% | 582,300 +34,400 | +6% | +$852K |
|
17
Karyopharm Therapeutics
KPTI
$61.7M
| $14.4M | 2.22% | 385,000 | – | – |
|
|
KERX
18
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $14.2M | 2.18% | 1,000,000 | – | – |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $11.2M | 1.72% | 300,000 | – | – |
|
20
DexCom
DXCM
$29.5B
| $11M | 1.7% | 200,000 | – | – |
|
|
XLRN
21
DELISTED
Acceleron Pharma Inc.
XLRN
| $9.74M | 1.5% | 250,000 -150,000 | -38% | -$5.84M |
|
22
BioCryst Pharmaceuticals
BCRX
$1.74B
| $9.73M | 1.5% | 800,000 -300,000 | -27% | -$3.65M |
|
|
GEVA
23
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $9.28M | 1.43% | 100,000 | – | – |
|
24
Novavax
NVAX
$1.21B
| $8.9M | 1.37% | 1,500,000 | – | – |
|
25
Sangamo Therapeutics
SGMO
$157M
| $7.61M | 1.17% | 500,000 | – | – |
|